Insulet CEO Ashley McEvoy Buys $160,000 in Shares After 55% Stock Decline. What Is This Telling Investors?

Brendan Coffey, The Motley Fool

Mon, August 24, 2026 at 4:33 PM GMT+3 5 min read

PODD -1.63%

Ashley McEvoy, the President and CEO of Insulet Corporation (NASDAQ:PODD), purchased 1,100 shares of common stock on Aug. 21, 2026. SEC Form 4 filing.

Transaction summary

Transaction value based on SEC Form 4 weighted average purchase price ($147.47); post-transaction value based on Aug. 21, 2026 market close ($148.16).

Key questions

What were the execution details of this open-market purchase?
The shares were acquired in multiple transactions at prices ranging from $147.42 to $147.62, resulting in a weighted average execution price of $147.47.
How does this transaction change the CEO's overall ownership structure?
The purchase expands the executive's direct holdings to 23,731 shares, a figure that includes 80 shares recently acquired via the company's employee stock purchase plan. McEvoy also maintains a nominal indirect position of four shares through a trust and holds derivative securities.
What is the current market value of the total equity stake?
As of the Aug. 21, 2026 market close of $148.16, the total position of 23,735 shares is valued at $3.52 million.
What is the recent financial context for Insulet Corporation?
The company, which develops and manufactures the Omnipod insulin delivery platform, reported trailing twelve-month revenue of $3.1 billion and net income of $375.3 million as of the latest reporting period.

Company Overview

Company Snapshot

Insulet Corporation develops, manufactures, and sells advanced insulin delivery systems, with the Omnipod platform serving as the primary revenue driver, including the Omnipod 5 automated insulin delivery system that integrates with continuous glucose monitors through proprietary algorithms.
The company generates revenue through the sale of proprietary insulin delivery pods and related management systems that enable patients with insulin-dependent diabetes to self-administer insulin therapy with enhanced convenience and control.
Insulet's primary customers are people with insulin-dependent diabetes in the United States and international markets, with revenue derived from direct patient sales, healthcare provider partnerships, and insurance reimbursement channels.

Insulet Corporation is a leading medical device manufacturer with a $10.3 billion market capitalization and $3.1 billion in trailing twelve month (TTM) revenue, positioning it as a significant player in the insulin delivery systems market. The company's competitive advantage is anchored in its proprietary Omnipod platform technology, which offers automated insulin delivery capabilities that differentiate its offerings from traditional insulin injection methods. With 5,400 employees and a focus on innovation in diabetes management, Insulet maintains strong profitability with TTM net income of $375.3 million, reflecting robust demand for its advanced insulin delivery solutions.

What this transaction means for investors

The dynamics around insider buying and selling mean investors should pay more attention to purchases than sells. That's because there are many reasons an insider may sell shares in a company. One reason could be the need to raise cash to fund a large personal expense. Another reason could be for a reasonable portfolio diversification unrelated to their outlook for the company. A third reason could be what investors fear most: a bearish outlook on the company's future.

But there is only one reason an insider buys stock -- they believe the share price is going up!

By that rule of thumb alone, McEvoy's purchase of Insulet shares is a bullish signal. That signal is further bolstered by studies showing that, more often than not, an insider purchase predicts a higher share price 30 days later.

McEvoy has been CEO of the business since April 2025, so she knows the business inside and out. Her investment now is a strong signal that she believes she and her team can reverse the stock's bearish trend.

In its latest quarter, reported at the start of August, sales grew 23% year over year on a constant currency basis -- that was better than expected.

The company recongizes that it needs to do more to get people who start using the Omnipod to stick with the treatment after the first three months, and is doing more personal guidance to encourage that. For the full fiscal year, management expects revenue to grow about 21%, with particular strength outside the U.S.

Under McEvoy's leadership, Insulet is doing more to explain its long-term growth path to investors. That she is buying now is a signal she believes she will be successful.

Should you buy stock in Insulet right now?

Before you buy stock in Insulet, consider this:

The Motley Fool Stock Advisor analyst team just identified what they believe are the 10 best stocks for investors to buy now… and Insulet wasn't one of them. The 10 stocks that made the cut could produce monster returns in the coming years.

Consider when Netflix made this list on December 17, 2004... if you invested $1,000 at the time of our recommendation, you'd have $429,223!* Or when Nvidia made this list on April 15, 2005... if you invested $1,000 at the time of our recommendation, you'd have $1,317,883!*

Now, it's worth noting Stock Advisor's total average return is 965% — a market-crushing outperformance compared to 212% for the S&P 500. Don't miss the latest top 10 list, available with Stock Advisor, and join an investing community built by individual investors for individual investors.

See the 10 stocks »

*Stock Advisor returns as of August 24, 2026.

Brendan Coffey has no position in any of the stocks mentioned. The Motley Fool has positions in and recommends Insulet. The Motley Fool has a disclosure policy.

Insulet CEO Ashley McEvoy Buys $160,000 in Shares After 55% Stock Decline. What Is This Telling Investors? was originally published by The Motley Fool